At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 469 enrolled
Drug / intervention
RTX-GRT7039 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Phase III Trial to Evaluate the Efficacy and Safety of Intra-articular Injections of RTX-GRT7039 in Adult Subjects With Pain Associated With Osteoarthritis of the Knee
In Brief
A Phase 3 clinical trial evaluating RTX-GRT7039 and Placebo for Osteoarthritis. Completed, enrolled 469 participants across 103 sites in 9 countries.
Detailed Summary
A double-blind, randomized, placebo-controlled, parallel-group, multi-site, clinical trial to confirm the efficacy and safety of repeated injections of RTX-GRT7039 versus placebo in patients who have pain associated with osteoarthritis of the knee despite standard of care.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis
CountriesCanada, Czechia, France, Germany, Italy, Japan, Mexico, Netherlands, Poland
Collaborators--
Timeline
Phase 3CompletedFinished
2023202420252026
First PostedFeb 2022
Enrollment StartAug 2022
Primary CompletionNov 2024
TodayJul 2026
First PostedFeb 21, 2022
Enrollment StartAug 26, 2022
Primary CompletionNov 18, 2024
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 4.4 years ago
Interventions
RTX-GRT7039drug
RTX-GRT7039 intra-articular injection.
Placebodrug
Placebo matching RTX-GRT7039 intra-articular injection.